Spruce Biosciences, Inc. Increase (Decrease) in Employee Related Liabilities
Spruce Biosciences, Inc. (SPRB) reported Increase (Decrease) in Employee Related Liabilities of -$582.00 thousand for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2022-08-10
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for the quarter ending 2022-06-30 was -$145.00K, a 158.94% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for the quarter ending 2022-03-31 was -$437.00K.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for the quarter ending 2021-12-31 was $426.00K, a 12.70% increase year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for the quarter ending 2021-09-30 was $36.00K, a 81.73% decline year-over-year.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for fiscal 2021 was $350.00K, a 97.74% increase from fiscal 2020.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for fiscal 2020 was $177.00K, a 69.06% decline from fiscal 2019.
- Spruce Biosciences, Inc. increase (decrease) in employee related liabilities for fiscal 2019 was $572.00K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$582.00K 10-Q · filed 2022-08-10 | -$156.00K derived: sum of 3 quarters · filed 2022-08-10 | -$120.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | -$437.00K 10-Q · filed 2022-05-11 | -$11.00K derived: sum of 2 quarters · filed 2022-05-11 | $25.00K derived: sum of 3 quarters · filed 2022-05-11 | $271.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-12-31 | $426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $462.00K derived: sum of 2 quarters · filed 2022-03-14 | $708.00K derived: sum of 3 quarters · filed 2022-08-10 | $350.00K 10-K · filed 2022-03-14 |
| 2021-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $282.00K derived: sum of 2 quarters · filed 2022-08-10 | -$76.00K 10-Q · filed 2021-11-15 | $302.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-06-30 | $246.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$112.00K 10-Q · filed 2022-08-10 | $266.00K derived: sum of 3 quarters · filed 2022-08-10 | $463.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$358.00K 10-Q · filed 2022-05-11 | $20.00K derived: sum of 2 quarters · filed 2022-05-11 | $217.00K derived: sum of 3 quarters · filed 2022-05-11 | $504.00K derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $575.00K derived: sum of 2 quarters · filed 2022-03-14 | $862.00K derived: sum of 3 quarters · filed 2022-03-14 | $177.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $484.00K derived: sum of 2 quarters · filed 2021-11-15 | -$201.00K 10-Q · filed 2021-11-15 | $247.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $287.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$398.00K 10-Q · filed 2021-08-10 | $50.00K derived: sum of 3 quarters · filed 2021-08-10 | |
| 2020-03-31 | -$685.00K 10-Q · filed 2021-05-12 | -$237.00K derived: sum of 2 quarters · filed 2021-05-12 | ||
| 2019-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-22 | $572.00K 10-K · filed 2021-03-22 | ||
| 2019-09-30 | $124.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |